Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974656147> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W1974656147 abstract "Objective: To report a case of peripheral and autonomic neuropathy following one cycle of bortezomib in a patient with newly diagnosed multiple myeloma. Case Summary: A 75-year-old male who was highly functional prior to therapy rapidly became bed-bound from hypotension, syncope, and peripheral neuropathy after initiating bortezomib. Orthostatic hypotension and syncope persisted despite exclusion of infection and endocrine derangements and his receiving adequate intravenous hydration. Five weeks after this single cycle, the patient had a complete treatment response, including undetectable M-spike, improved anemia, and return to baseline renal function. An objective causality assessment revealed that an adverse drug event was probable. Discussion: Although neurotoxicity is an adverse effect of bortezomib, a MEDLINE search revealed little evidence on autonomic neuropathy, such as orthostatic hypotension and syncope. Also unique is the patient's complete treatment response following this single cycle. One explanation for the toxicities and dramatic treatment response is increased bortezomib exposure due to decreased drug metabolism. Both drug interactions and genetic polymorphisms can reduce bortezomib metabolism via effects on cytochrome P450 enzymes. Our patient was concomitantly taking 4 CYP inhibitors; amiodarone and omeprazole were longstanding, and ciprofloxacin and fluconazole were recently initiated prior to chemotherapy. Of these, fluconazole inhibits CYP2C9, 2C19, and 3A4; amiodarone inhibits CYP3A4, 1A1, 1A2, 2B6, and 2D6; ciprofloxacin inhibits CYP1A2 and 3A4; and omeprazole inhibits CYP1A2, 2C19, 2C9, 2D6, and 3A4. Similarly, genetic variables affect CYP enzymes. Genetic testing can predict response to bortezomib therapy, but pretherapy testing is not standard practice due to availability and cost, as in our patient's case. Conclusions: CYP-inhibiting drugs and many genetic polymorphisms can reduce bortezomib metabolism and increase serum concentrations of the drug, but guidelines on drug-drug interactions, monitoring, and genetic testing prior to bortezomib toxicity are needed." @default.
- W1974656147 created "2016-06-24" @default.
- W1974656147 creator A5026288918 @default.
- W1974656147 creator A5042993381 @default.
- W1974656147 creator A5070501986 @default.
- W1974656147 creator A5085516894 @default.
- W1974656147 date "2012-09-01" @default.
- W1974656147 modified "2023-09-26" @default.
- W1974656147 title "Profound Neurotoxicity and Treatment Response following One Cycle of Bortezomib Therapy in an Elderly Male with Multiple Myeloma" @default.
- W1974656147 cites W1703321169 @default.
- W1974656147 cites W1997169121 @default.
- W1974656147 cites W2048285147 @default.
- W1974656147 cites W2067978628 @default.
- W1974656147 cites W2084842992 @default.
- W1974656147 cites W2096207943 @default.
- W1974656147 cites W2108075231 @default.
- W1974656147 cites W2111810335 @default.
- W1974656147 cites W2124560610 @default.
- W1974656147 cites W2152558468 @default.
- W1974656147 cites W2161231801 @default.
- W1974656147 cites W2171783170 @default.
- W1974656147 doi "https://doi.org/10.1177/875512251202800503" @default.
- W1974656147 hasPublicationYear "2012" @default.
- W1974656147 type Work @default.
- W1974656147 sameAs 1974656147 @default.
- W1974656147 citedByCount "1" @default.
- W1974656147 countsByYear W19746561472013 @default.
- W1974656147 crossrefType "journal-article" @default.
- W1974656147 hasAuthorship W1974656147A5026288918 @default.
- W1974656147 hasAuthorship W1974656147A5042993381 @default.
- W1974656147 hasAuthorship W1974656147A5070501986 @default.
- W1974656147 hasAuthorship W1974656147A5085516894 @default.
- W1974656147 hasConcept C126322002 @default.
- W1974656147 hasConcept C143998085 @default.
- W1974656147 hasConcept C2776364478 @default.
- W1974656147 hasConcept C2777478702 @default.
- W1974656147 hasConcept C2779491297 @default.
- W1974656147 hasConcept C29730261 @default.
- W1974656147 hasConcept C71924100 @default.
- W1974656147 hasConceptScore W1974656147C126322002 @default.
- W1974656147 hasConceptScore W1974656147C143998085 @default.
- W1974656147 hasConceptScore W1974656147C2776364478 @default.
- W1974656147 hasConceptScore W1974656147C2777478702 @default.
- W1974656147 hasConceptScore W1974656147C2779491297 @default.
- W1974656147 hasConceptScore W1974656147C29730261 @default.
- W1974656147 hasConceptScore W1974656147C71924100 @default.
- W1974656147 hasLocation W19746561471 @default.
- W1974656147 hasOpenAccess W1974656147 @default.
- W1974656147 hasPrimaryLocation W19746561471 @default.
- W1974656147 hasRelatedWork W2011372640 @default.
- W1974656147 hasRelatedWork W2027279497 @default.
- W1974656147 hasRelatedWork W2159739496 @default.
- W1974656147 hasRelatedWork W2318150798 @default.
- W1974656147 hasRelatedWork W2329828648 @default.
- W1974656147 hasRelatedWork W2351739379 @default.
- W1974656147 hasRelatedWork W2369248520 @default.
- W1974656147 hasRelatedWork W2369637210 @default.
- W1974656147 hasRelatedWork W2530199617 @default.
- W1974656147 hasRelatedWork W2562106677 @default.
- W1974656147 hasRelatedWork W2581654066 @default.
- W1974656147 hasRelatedWork W2595167555 @default.
- W1974656147 hasRelatedWork W2607239200 @default.
- W1974656147 hasRelatedWork W2889424623 @default.
- W1974656147 hasRelatedWork W2920508284 @default.
- W1974656147 hasRelatedWork W2941091272 @default.
- W1974656147 hasRelatedWork W3005739460 @default.
- W1974656147 hasRelatedWork W3009943666 @default.
- W1974656147 hasRelatedWork W3130187693 @default.
- W1974656147 hasRelatedWork W8080459 @default.
- W1974656147 isParatext "false" @default.
- W1974656147 isRetracted "false" @default.
- W1974656147 magId "1974656147" @default.
- W1974656147 workType "article" @default.